All In Biotech

Drug Trial Radar · NCT01037543

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and PK of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Japanese and Caucasian Subjects.

Last checked: Nov 20, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Nov 2009

Primary completion

Feb 2011

Study completion Apr 2011

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study Design * Randomized, double-blind, placebo-controlled, escalating single-dose design. * Six ascending dose cohorts * In each cohorts, subjects will be randomized to receive a single dose of HM10460A, placebo (negative control), or Neulasta® (positive control). * Primary Objective * to assess the safety and tolerability of single escalating subcutaneous doses of HM10460A in healthy adult Japanese and Caucasian subjects.

Conditions

  • Healthy

Interventions

  • HM10460A or placebo or NeulastaDrug

    Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs assessments, and adverse effects (AEs).Time frame: Time points where appropriate.
  2. Samples for immunogenicityTime frame: Days -1, 15, 22, and 42.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    California City, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.